Could a Two-Punch approach beat tough lymphoma?
NCT ID NCT06854159
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 23 times
Summary
This study tests whether adding the drug odronextamab before and after standard CAR T-cell therapy helps people with diffuse large B-cell lymphoma that has returned or not responded to prior treatments. About 34 adults will receive odronextamab to help their immune T-cells find and kill cancer cells, alongside the usual CAR T treatment. The goal is to see if this combination leads to more complete remissions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of California Davis Comprehensive Cancer Center
RECRUITINGSacramento, California, 95817, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.